RxDoctor Payments Data

Shirley Earl, NP

Adult Health · Oneonta, NYNPI 1033634241

Payments from drug & device makers

$909in general payments, 2019–2025

Across 29 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$283
  • Cvrx, Inc.$144
  • Lexicon Pharmaceuticals, Inc.$83
  • Amgen$75
  • Boehringer Ingelheim$65
  • Novartis$47
  • plus $211 from 9 others

What the payments were for

  • Food & beverage$909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$909 in reported general payments places this provider in the 65th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$27,404
Medicare patients
298
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$174,515
EntrestoSacubitril/Valsartan34$36,885
Metoprolol Succinate221$4,088
Rosuvastatin Calcium102$1,931
Atorvastatin Calcium83$1,418
Eplerenone11$1,288
Ezetimibe26$816
Amlodipine Besylate109$763
Losartan Potassium69$707
Isosorbide Mononitrate ErIsosorbide Mononitrate35$615
Torsemide56$604
Spironolactone66$438
Carvedilol43$430
ClopidogrelClopidogrel Bisulfate24$410
Metoprolol Tartrate55$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$174,515125 claims
NovartisEntresto$47$36,88534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,828 adult health providers in New York.

Other adult health in Oneonta

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →